Could a diabetes drug curb alcohol cravings and save livers?

NCT ID NCT07046819

Recruiting now Disease control Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tests whether tirzepatide, a drug approved for weight management, can help people with alcohol use disorder and related liver disease drink less and improve liver health. 120 adults will receive weekly injections of tirzepatide or a placebo for 12 weeks. Researchers will measure changes in body weight, liver fat, and drinking behaviors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (a weight management drug)
What this could lead to: If it works, this could point toward a new treatment that helps people drink less and improves liver health.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not reduce alcohol cravings or liver damage more than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Body Weight metabolic dysfunction and alcohol associated liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER METABOLIC ALCOHOL-ASSOCIATED LIVER DISEASE

Contacts and locations

Show contact details

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.